Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
Public ClinicalTrials.gov record NCT00324155. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this clinical research study is to examine the safety and effectiveness (how well the drug works) of two different treatments for patients with melanoma. One treatment is an investigational compound (a drug that is not currently approved by the United States Food and Drug Administration \[FDA\]), know as Ipilimumab (also known as MDX-010 or BMS-734016) together with an approved chemotherapy drug called Dacarbazine
Study identification
- NCT ID
- NCT00324155
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 681 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2006 (Type not available)
- Primary completion
- Jan 2011 (Actual)
- Completion
- Oct 2013 (Actual)
- Last update posted
- Nov 3, 2014
2006 – 2013
United States locations
- U.S. sites
- 32
- U.S. states
- 19
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pacific Cancer Medical Center | Anaheim | California | 92801 | — |
| Wilshire Oncology Medical Group Inc | La Verne | California | 91750 | — |
| The Angeles Clinic And Research Institute | Los Angeles | California | 90025 | — |
| Comprehensive Cancer Center | Palm Springs | California | 92262 | — |
| Sharp Clinical Oncology Research | San Diego | California | 92123 | — |
| Saint Francis Hospital And Medical Center | Hartford | Connecticut | 06105 | — |
| Hematology Oncology, P.C. | Stamford | Connecticut | 06902-3628 | — |
| Cancer Specialists Of North Florida Beaches | Jacksonville | Florida | 32256 | — |
| Orlando Health, Inc. M.D. Anderson Cancer Center Orlando | Orlando | Florida | 32806 | — |
| Hematology Oncology Associates Of The Treasure Coast | Port Saint Lucie | Florida | 34952 | — |
| University Of Chicago | Chicago | Illinois | 60637 | — |
| Mid-Illinois Hematology/Oncology Associates, Ltd. | Normal | Illinois | 61761 | — |
| Oncology Specialists, Sc | Park Ridge | Illinois | 60068 | — |
| Central Indiana Cancer Centers | Fishers | Indiana | 46037 | — |
| Indiana University Cancer Center | Indianapolis | Indiana | 46202 | — |
| Hutchinson Clinic, Pa | Hutchinson | Kansas | 67502 | — |
| Kentucky Cancer Clinic | Hazard | Kentucky | 41701 | — |
| Greater Baltimore Medical Center | Baltimore | Maryland | 21204 | — |
| Sinai Hospital Of Baltimore | Baltimore | Maryland | 21215 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| Ellis Fischel Cancer Center | Columbia | Missouri | 65203 | — |
| St Joseph Oncology Inc | Saint Joseph | Missouri | 64507 | — |
| University Of New Mexico Cancer Center | Albuquerque | New Mexico | 87106 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Blumenthal Cancer Center | Charlotte | North Carolina | 28204 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| St. Luke'S Hospital & Health Network | Bethlehem | Pennsylvania | 18015 | — |
| Lowcountry Hematology & Oncology, Pa | Mt. Pleasant | South Carolina | 29464 | — |
| Thompson Cancer Survival Center | Knoxville | Tennessee | 37916 | — |
| Vanderbilt-Ingram Cancer Ctr | Nashville | Tennessee | 37232 | — |
| Joe Arrington Cancer Research And Treatment Center | Lubbock | Texas | 79410 | — |
| Virginia Cancer Institute | Richmond | Virginia | 23226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 95 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00324155, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 3, 2014 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00324155 live on ClinicalTrials.gov.